Skip to main content
Sopharma AD logo

Sopharma AD — Investor Relations & Filings

Ticker · SFA ISIN · BG11SOSOBT18 LEI · 097900BGGW0000048796 BSOBGN Manufacturing
Open in API
Filings indexed 1,485 across all filing types
Latest filing 2022-05-30 Regulatory Filings
Country BG Bulgaria
Listing BSOBGN SFA

About Sopharma AD

https://www.sopharmagroup.com/

Sopharma AD is a pharmaceutical company founded in 1933 that specializes in the production, distribution, and export of a wide range of medical products. The company's portfolio includes prescription (Rx) and over-the-counter (OTC) medicines, encompassing both branded and generic drugs. A key area of focus is its traditional plant-based products. Sopharma develops treatments for various conditions, including liver disease, pain management, and smoking cessation. Operating from EU-GMP certified facilities, the company also provides contract manufacturing services and has an established presence in over 40 international markets.

Recent filings

Filing Released Lang Actions
Consolidated financial report according to IFRS as at 31 March 2022
Regulatory Filings Classification · 19% confidence
2022-05-30 Polish
Sales revenues for April 2022
Earnings Release Classification · 100% confidence The document is very short (565 characters) and contains a 'NOTIFICATION' regarding sales performance for April 2022 and the four-month period. It provides key performance indicators (KPIs) like percentage increases in sales, but it is not a comprehensive financial report (like 10-K or IR). This format, which announces key operational/financial highlights for a period without being the full report, strongly aligns with an Earnings Release (ER). It is an initial announcement of period results. Q2 2022
2022-05-05 English
Individual financial report according to IFRS as at 31 March 2022
Regulatory Filings Classification · 19% confidence
2022-04-29 Polish
Invitation and materials for the Annual General Meeting of Shareholders of Sopharma AD to be held on 3 June 2022
AGM Information Classification · 19% confidence
2022-04-29 Polish
Disclosure of the Annual Audited Consolidated Financial Statements of Sopharma Group as at 31 December 2021
Annual Report (ESEF) Classification · 100% confidence FY 2021
2022-04-28 Polish
Sales revenues for March 2022
Regulatory Filings Classification · 99% confidence The document is titled 'Current report №14/ 2022 Dated April 5, 2022' and provides a brief summary of sales performance for March 2022 and the first quarter, noting specific percentage changes in domestic and export sales, and attributing changes to geopolitical events (Russia's invasion of Ukraine). This format—a brief, periodic update on key operational/financial metrics without the full detail of a comprehensive report—is characteristic of an Earnings Release (ER) or a general regulatory notification. Given the brevity (736 chars) and the nature of reporting period-specific sales figures, it aligns best with an Earnings Release (ER) which typically contains the initial highlights. It is too brief to be an Interim Report (IR) or Annual Report (10-K).
2022-04-05 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.